Skip to content

VESALE PHARMACEUTICA

Active
Public limited companyfounded 1994active for 32 yearsRue Jean Sonet,Isnes 29, 5032 Gembloux, BelgiumKBO/BCE: BE 0452.282.591
Summary

VESALE PHARMACEUTICA has been active since 1994 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3.1m and a net result of -€362,888. Equity is growing by about 5% per year across the filed financial years. Its solvency ranks better than 83% of 6,158 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysisFollow ReportCompare
VESALE PHARMACEUTICAActiveChecked score 90/100
Risk analysis ReportCompare

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
8th largest company by equity in Gembloux, Wholesale and retail trade sector2 sites
Size
≈ €9.5mturnover 2025, estimated
Staff
2.8 FTE
Equity
€3.1m
Loss
-€362,888
Turnover estimated from the gross margin
Financial health
90 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.2%
Structure
Parent
Ceres Pharma · 100%
Holdings
1
Auditor: BV PwC Bedrijfsrevisoren2025 accounts 2 days early3 of 11 deeds summarised
Why 90raises riskLoss of €362,888 (financial year 2025)1 change of registered office in 24 monthslowers riskSize: 2.8 FTE, total assets €4.0mLiquidity: current ratio 3.52, cash €1.5mShow the evidence

Checked score

Score 2025
90 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 62% of its sector peers (NACE 46, micro)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 100=
equity 77.1% of total assets
Liquidity 89+42
short-term debt 22.9% · cash 37.4%
Profitability 57-18
return on assets -9.0%
Bankruptcy probability, 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.4% (26,900 companies, NACE 46, micro)
Last 24 months 11-2024: 0.8% 12-2024: 0.8%● unchanged vs 11-2024 01-2025: 0.8%● unchanged vs 12-2024 02-2025: 0.8%● unchanged vs 01-2025 03-2025: 0.8%● unchanged vs 02-2025 04-2025: 0.8%● unchanged vs 03-2025 05-2025: 0.8%● unchanged vs 04-2025 06-2025: 0.8%● unchanged vs 05-2025 07-2025: 0.9%▲ +0.1 percentage points vs 06-2025 08-2025: 1.3%▲ +0.4 percentage points vs 07-2025highest value 09-2025: 0.1%▼ -1.2 percentage points vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025lowest value 02-2026: 0.4%▲ +0.3 percentage points vs 01-2026 03-2026: 0.4%● unchanged vs 02-2026 04-2026: 0.4%● unchanged vs 03-2026 05-2026: 0.5%▲ +0.1 percentage points vs 04-2026 06-2026: 0.6%▲ +0.1 percentage points vs 05-2026 07-2026: 0.6%● unchanged vs 06-2026 08-2026: 0.2%▼ -0.4 percentage points vs 07-2026 09-2026: 0.2%● unchanged vs 08-2026 10-2026: 0.2%● unchanged vs 09-2026
Credit of up to €270,000 on 30-day terms is acceptable
Liquidity ample (current ratio 3.52, compared with 3.98 in 2024, above the usual 1.5; short-term debt: 22.9% and cash: 37.4% of total assets), and 22.9% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro): better than 90% on solvency, 88% on liquidity, 43% on profitability and 25% on growth.

The bankruptcy probability was computed on 30-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · Loss of €362,888 (financial year 2025)
NBB · annual accounts
lowers risk · Size: 2.8 FTE, total assets €4.0m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
lowers risk · Liquidity: current ratio 3.52, cash €1.5m
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
2 days early
2024
14 days late
2023
372 days late
2022
29 days late
2021
29 days late
2020
31 days late
2019
16 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 65 days after the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 August (4 of the last 5 filed years within 31 days of that day).
Companies Code · seven months
Where today falls in the filing period
31-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Appointment: PwC Bedrijfsrevisoren BV (statutory auditor)Permanent representative: Wouter Coppens
  3. Registered officeRegistered-office move · Director in…

Key points

  • Caution: From profit to loss in 2025after €242,636 in 2024 -€362,888 View
  • Caution: Among the weakest 8% on net resultsector median €112,134 · 6,092 companies -€362,888 View
  • Controlled by Ceres Pharmaultimately: Ceres Invest 100% View

By topic

Financials

Financial year
2025
Total assets
€4.0m
Loss
-€362,888
Solvency
77.1%
Go to Financials

Board & ownership

Board
3 members
Parent
Ceres Pharma · 100%
Auditor
BV PwC Bedrijfsrevisoren
  • AquitaniaDirector
  • Jehan Lienart van Lidth de JeudeDirector
  • MD CONSULTDirector
Go to Board & ownership

Timeline

Events
36
Since
1996
Next accounts
by 31-07-2027
  1. 14-08-2025Annual accounts filed
  2. 07-08-2025Annual accounts filed
  3. 18-06-2025Resignations: Vesale Pharma International, Rode Ventures BV…
Go to Timeline

Company details

Sites
2
Legal form
Public limited company
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Founded
16-03-1994
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Key facts about VESALE PHARMACEUTICA

What is the company number of VESALE PHARMACEUTICA?
0452.282.591. In Belgium the VAT number is the company number with BE in front: BE 0452.282.591.
Where is VESALE PHARMACEUTICA based?
The registered office is at Rue Jean Sonet,Isnes 29, 5032 Gembloux.Company details
What does VESALE PHARMACEUTICA do?
According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of VESALE PHARMACEUTICA?
Public limited company (NV).
When was VESALE PHARMACEUTICA founded?
On 16-03-1994.
Is VESALE PHARMACEUTICA still active?
Yes, VESALE PHARMACEUTICA is an active enterprise in the KBO register.
How many employees does VESALE PHARMACEUTICA have?
On average 2.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of VESALE PHARMACEUTICA?
€5.9m in financial year 2021, according to the filed annual accounts.
Is VESALE PHARMACEUTICA profitable?
In financial year 2025, VESALE PHARMACEUTICA made a loss of €362,888.
Where can I find the annual accounts of VESALE PHARMACEUTICA?
VESALE PHARMACEUTICA filed 30 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of VESALE PHARMACEUTICA due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to VESALE PHARMACEUTICA

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies Which other companies belong to the same group?Ceres Invest · 12 companies

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure